ILCA | Association Partnerships

Latest from ILCA


Checkpoint Inhibition Plus Ablation Shows Promise in Advanced HCC

September 05, 2021

Efficacy and safety have been demonstrated with the combination of durvalumab with tremelimumab and transcatheter arterial chemoembolization or radiofrequency ablation in advanced hepatocellular carcinoma.